These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28456380)

  • 21. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease).
    Sun Y; Almomani R; Breedveld GJ; Santen GW; Aten E; Lefeber DJ; Hoff JI; Brusse E; Verheijen FW; Verdijk RM; Kriek M; Oostra B; Breuning MH; Losekoot M; den Dunnen JT; van de Warrenburg BP; Maat-Kievit AJ
    Hum Mutat; 2013 May; 34(5):706-13. PubMed ID: 23418007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation.
    Chen ZR; Liu DT; Meng H; Liu L; Bian WJ; Liu XR; Zhu WW; He Y; Wang J; Tang B; Su T; Yi YH
    Seizure; 2019 Jul; 69():180-185. PubMed ID: 31059981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
    Sondhi D; Johnson L; Purpura K; Monette S; Souweidane MM; Kaplitt MG; Kosofsky B; Yohay K; Ballon D; Dyke J; Kaminksy SM; Hackett NR; Crystal RG
    Hum Gene Ther Methods; 2012 Oct; 23(5):324-35. PubMed ID: 23131032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
    Passini MA; Dodge JC; Bu J; Yang W; Zhao Q; Sondhi D; Hackett NR; Kaminsky SM; Mao Q; Shihabuddin LS; Cheng SH; Sleat DE; Stewart GR; Davidson BL; Lobel P; Crystal RG
    J Neurosci; 2006 Feb; 26(5):1334-42. PubMed ID: 16452657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partial genetic suppression of a loss-of-function mutant of the neuronal ceroid lipofuscinosis-associated protease TPP1 in Dictyostelium discoideum.
    Phillips JE; Gomer RH
    Dis Model Mech; 2015 Feb; 8(2):147-56. PubMed ID: 25540127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An integrated strategy for the diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven Latin American patients.
    Kohan R; Cismondi IA; Kremer RD; Muller VJ; Guelbert N; Anzolini VT; Fietz MJ; Ramírez AM; Halac IN
    Clin Genet; 2009 Oct; 76(4):372-82. PubMed ID: 19793312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.
    Ghosh A; Rangasamy SB; Modi KK; Pahan K
    J Neurochem; 2017 May; 141(3):423-435. PubMed ID: 28199020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic Analysis of Brain and Cerebrospinal Fluid from the Three Major Forms of Neuronal Ceroid Lipofuscinosis Reveals Potential Biomarkers.
    Sleat DE; Tannous A; Sohar I; Wiseman JA; Zheng H; Qian M; Zhao C; Xin W; Barone R; Sims KB; Moore DF; Lobel P
    J Proteome Res; 2017 Oct; 16(10):3787-3804. PubMed ID: 28792770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical study in Chinese patients with late-infantile form neuronal ceroid lipofuscinoses.
    Chang X; Huang Y; Meng H; Jiang Y; Wu Y; Xiong H; Wang S; Qin J
    Brain Dev; 2012 Oct; 34(9):739-45. PubMed ID: 22245569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML
    Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
    Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
    Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Tracy CJ; Whiting RE; Pearce JW; Williamson BG; Vansteenkiste DP; Gillespie LE; Castaner LJ; Bryan JN; Coates JR; Jensen CA; Katz ML
    Exp Eye Res; 2016 Nov; 152():77-87. PubMed ID: 27637672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late infantile neuronal ceroid lipofuscinosis: a new mutation in Arabs.
    Goldberg-Stern H; Halevi A; Marom D; Straussberg R; Mimouni-Bloch A
    Pediatr Neurol; 2009 Oct; 41(4):297-300. PubMed ID: 19748052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glial fibrillary acidic protein is elevated in the lysosomal storage disease classical late-infantile neuronal ceroid lipofuscinosis, but is not a component of the storage material.
    Xu S; Sleat DE; Jadot M; Lobel P
    Biochem J; 2010 May; 428(3):355-62. PubMed ID: 20370715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical tryptophan and Ca2+ in activation and catalysis of TPPI, the enzyme deficient in classic late-infantile neuronal ceroid lipofuscinosis.
    Kuizon S; DiMaiuta K; Walus M; Jenkins EC; Kuizon M; Kida E; Golabek AA; Espinoza DO; Pullarkat RK; Junaid MA
    PLoS One; 2010 Aug; 5(8):e11929. PubMed ID: 20689811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.
    Sleat DE; El-Banna M; Sohar I; Kim KH; Dobrenis K; Walkley SU; Lobel P
    Mol Genet Metab; 2008 Jun; 94(2):222-33. PubMed ID: 18343701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.
    Kohan R; Carabelos MN; Xin W; Sims K; Guelbert N; Cismondi IA; Pons P; Alonso GI; Troncoso M; Witting S; Pearce DA; Dodelson de Kremer R; Oller-Ramírez AM; Noher de Halac I
    Gene; 2013 Mar; 516(1):114-21. PubMed ID: 23266810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.